Denali Therapeutics Inc. - COMMON STOCK (DNLI)

Historical Holders from Q4 2017 to Q3 2025

Symbol: DNLI on Nasdaq
Type / Class: Equity / COMMON STOCK
Shares outstanding: 147,179,178
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 135,492,171
Holdings value: $1,967,348,087
% of all portfolios: 0.01%
Number of holders: 234
Number of buys: 121
Number of sells: -90
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Denali Therapeutics Inc. - COMMON STOCK (DNLI)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
BlackRock, Inc.	7.2%		$173,095,065		10,490,610		BlackRock, Inc.	31 Mar 2025
FMR LLC	5.8%		$123,948,417		8,536,392		FMR LLC	30 Sep 2025
WELLINGTON MANAGEMENT GROUP LLP	3.9%		$82,251,923		5,664,733		Wellington Management Group LLP	30 Jun 2025
Capital Research Global Investors	3.8%		$90,373,982		5,477,211		Capital Research Global Investors	31 Dec 2024
BAILLIE GIFFORD & CO	5.6%	-23%	$31,927,897	-$7,858,384	2,198,891	-20%	BAILLIE GIFFORD & CO	30 Jun 2025

Institutional Holders of Denali Therapeutics Inc. - COMMON STOCK (DNLI)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	135,492,171	$1,967,348,087	-$29,612,927	$1,552,188	$2,928,684	$14.52	234
2025 Q2	137,594,175	$1,925,023,022	+$63,128,608	$215,446	$1,836,887	$13.99	228
2025 Q1	132,874,634	$1,807,534,753	+$50,388,875	$107,401	$277,338	$13.60	219
2024 Q4	127,929,251	$2,607,162,085	+$11,750,487	$749,984	$1,285,978	$20.38	222
2024 Q3	126,754,706	$3,691,746,017	+$83,332,107	$681,642	$1,765,278	$29.13	215
2024 Q2	123,900,320	$2,876,933,310	+$81,781,105	$889,326	$2,951,262	$23.22	202
2024 Q1	122,410,671	$2,512,114,129	+$149,691,318	$1,852,956	$1,887,840	$20.52	208
2023 Q4	115,037,875	$2,465,293,115	+$48,272,802	$1,476,598	$1,807,082	$21.46	208
2023 Q3	108,753,813	$2,243,639,062	+$15,314,130	$693,168	$1,600,888	$20.63	194
2023 Q2	107,385,972	$3,168,950,262	+$5,897,175	$398,385	$557,739	$29.51	198
2023 Q1	108,017,472	$2,487,976,875	+$45,585,839	$7,948,800	$864,000	$23.04	198
2022 Q4	106,059,670	$2,949,511,974	+$353,989,026	$250,290	$1,501,740	$27.81	195
2022 Q3	92,590,614	$2,841,171,715	-$31,157,203	$482,000	$2,614,000	$30.69	192
2022 Q2	92,689,565	$2,727,755,557	+$180,988,868	$518,000	$1,389,000	$29.43	177
2022 Q1	86,720,578	$2,790,606,045	+$40,452,227	$1,605,000	$783,000	$32.17	177
2021 Q4	85,268,721	$3,803,185,901	+$18,535,233	$9,272,000	$2,586,000	$44.60	204
2021 Q3	82,102,816	$4,142,844,228	+$169,589,833	$5,146,000	$12,346,000	$50.45	205
2021 Q2	77,780,665	$6,099,806,785	+$34,022,640	$7,624,000	$29,948,000	$78.44	204
2021 Q1	77,751,278	$4,438,997,286	+$78,721,718	$4,220,000	$13,127,000	$57.10	213
2020 Q4	66,445,136	$5,564,771,315	+$193,800,989	$5,722,000	$28,496,600	$83.76	199
2020 Q3	82,769,611	$2,965,793,194	+$14,445,549	$2,504,000	$1,792,000	$35.83	168
2020 Q2	82,768,394	$2,001,309,869	+$63,425,607	$322,000	$820,000	$24.18	142
2020 Q1	80,458,775	$1,408,929,438	+$149,773,734	$434,000	$0	$17.51	127
2019 Q4	70,860,285	$1,234,391,510	-$9,532,468	$840,000	$660,000	$17.42	107
2019 Q3	71,458,501	$1,094,801,327	-$4,573,862	$1,488,000	$849,000	$15.32	112
2019 Q2	63,549,412	$1,319,252,281	+$54,502,235	$328,000	$1,030,000	$20.76	113
2019 Q1	61,057,319	$1,417,761,132	+$44,297,416			$23.22	113
2018 Q4	68,108,281	$1,407,070,297	-$256,309			$20.66	89
2018 Q3	58,053,077	$1,262,045,654	+$108,737,022	$0		$21.74	76
2018 Q2	53,287,730	$812,631,603	+$13,608,742	$191,000		$15.25	65
2018 Q1	60,832,830	$1,196,651,992	+$60,152,032			$19.69	56
2017 Q4	58,144,510	$909,309,000	+$907,640,000			$15.64	45